VIVEX Biologics: The science of extraordinary

VIVEX is expanding our Amnion & Wound Care Distribution Network. Interested in becoming a distribution partner? Click here to learn more.

ABOUT
PRODUCTS
QUALITY AND SAFETY
- Certificates and Licenses
CONTACT

ABOUT
PRODUCTS
QUALITY AND SAFETY
- Certificates and Licenses
CONTACT

LEADERSHIP TEAM

John A. McCallum

Executive Chairman

Barry Salzman

Co-President and Chief Operating Officer

Reinaldo (Rey) Pascual

Co-President and General Counsel

Vanessa Baron

Vice President of Research and Development

Erin Chance

Assistant General Counsel & Chief Compliance Officer

Brian Fromhold

Senior Vice President of Finance

Timothy Ganey, Ph.D

Chief Technology Officer

Santiago Osorio, CTBS

Vice President of Operations

Michele Pablos, MBA

Vice President of Ortho & Fusion Therapies/Strategic Accounts

Craig Sincaglia

Vice President of Quality System and Regulatory Affairs

H. Thomas Temple, MD

Chief Medical Officer

Laura Trivette

Vice President of Health Policy and Reimbursement

BOARD OF DIRECTORS

John A. McCallum

Executive Chairman

Tracy S. Anderson

Founder, Vice Chairman of the Board

Barry Salzman

Vice Chairman

James K. Price

J. Miguel Fernandez de Castro, MAcc

U. Bertram Ellis, Jr., MBA

Tim Taylor

Richard Perlman, MBA

Erin Chance, Assistant General Counsel & Chief Compliance Officer

Erin Chance joined VIVEX Biologics in 2019 as Assistant General Counsel and became Chief Compliance Officer in 2023. She is responsible for all areas of legal and healthcare compliance matters for VIVEX.

Ms. Chance has over 20 years of experience in the legal industry, including practicing in the Atlanta office of Kilpatrick Stockton and running her own successful law firm specializing in providing corporate legal advice and assistance to in-house legal counsel as well as providing general corporate advice, contract review and negotiation, and legal analysis to companies, nonprofits, and other law firms.

Ms. Chance received both her Juris Doctor and Bachelor of Arts degrees from the University of Georgia with honors. She also earned a Graduate Certificate in Pharmaceutical and Medical Device Law and Compliance from Seton Hall Law School and is a Certified Tissue Bank Specialist. Ms. Chance serves on the Board of Directors of Press On, a nonprofit that advocates and fundraises for less toxic, more effective treatments for childhood cancer, and Children Inspiring Hope, a nonprofit providing children in Ghana with water, self-sustaining farming skills, educational opportunities, and an opportunity to connect cross-culturally through arts and education with students in the United States.

Vanessa Baron, Vice President of Research and Development

Vanessa Baron joined VIVEX Biologics in 2016 and is currently Vice President of Research and Development. In this role, Ms. Baron leads a team of engineers in developing innovative products to help further VIVEX’s goals of improving healthcare.

Ms. Baron has years of experience within R&D, previously holding positions of product development engineer and director. She holds a Bachelor’s degree from Florida International University in biomechanical/medical engineering.

Craig Sincaglia, Vice President of Quality System and Regulatory Affairs

Craig Sincaglia joined VIVEX Biologics in 2023 as Vice President of Quality System and Regulatory Affairs. Mr. Sincaglia has more than 25 years of experience in Quality, Compliance, Operations, Engineering, and Business Development.

Prior to joining VIVEX, Mr. Sincaglia was the Director of Operational Excellence at BioReference Laboratories. Prior thereto, he held numerous positions at MTF Biologics, including Director of Quality Assurance and Manager of Process Engineering.

Mr. Sincaglia holds a Bachelor’s degree from New Jersey Institute of Technology in Chemical Engineering and is a master black belt in Lean Six Sigma.

Peter L. Wehrly – Chief Executive Officer (CEO)

Peter L. Wehrly is a seasoned leader in the medical device and biotech industries and brings extensive leadership experience to VIVEX Biologics. As CEO, Mr. Wehrly is responsible for delivering consistent top-line growth and operational efficiencies across the organization.

Prior to joining VIVEX Biologics in 2019, Mr. Wehrly served as CEO and Chairman of the Board for Synaptive Medical, a Toronto-based company that focuses on innovative technology and medical devices for the neuro-cranial and spinal markets. He also held several senior leadership positions with Medtronic, Inc., including Senior Vice President, President of Spinal & Biologics, and President of Medtronic Sofamor Danek. He also directed global business in Western Europe, Japan, Canada, Australia and New Zealand as Group President for Covidien.

During his 17 years with DePuy Orthopedics, a Johnson & Johnson company, Mr. Wehrly was able to leverage his leadership abilities into various managerial roles of increasing responsibilities, including Vice President of Sales & Marketing and President of DePuy OrthoTech. He has also served in numerous board positions at for-profit and not-for-profit organizations.

Mr. Wehrly holds a Bachelor of Science in Management degree from Ball State University and has completed several advanced management programs, including one at the IMD Internal School of Management in Lausanne, Switzerland.

Lou Barnes, B.S.Ed., MBA, CTBS – President and Chief Operating Officer (COO)

Lou Barnes is a veteran in the tissue banking industry, with more than 26 years of tissue banking experience. Mr. Barnes joined VIVEX Biologics in 2015 from DCI Donor Services Tissue Bank, based in Nashville TN, where he served as the Executive Director.

Mr. Barnes has led and managed tissue banks for both the for-profit and not-for-profit sectors and also served as the Chairman to the American Association of Tissue Banks (AATB), as well as a member of its Board of Governors.

He holds a Bachelor of Science degree from the University of Georgia and an MBA from the University of Alabama. Mr. Barnes is also a designated Certified Tissue Bank Specialist (CTBS).

Timothy Ganey, Ph.D – Chief Technology Officer

Dr. Timothy Ganey joined VIVEX Biologics in 2017 as Chief Technology Officer after serving as the Director of Orthopedic Research and Director for the residency program at Atlanta Medical Center and Director of the Atlanta Learning Center. As CTO, he has been instrumental in developing several technological initiatives for VIVEX Biologics.

Prior to his time at Atlanta Medical Center and Atlanta Learning Center, Dr. Ganey served as the President of the US division of CO.DON Tissue Engineering, where he and his team developed and commercialized a portfolio of cell-based therapeutics for cartilage and bone.

Dr. Ganey has been instrumental in the development of numerous technological advancements, including the use of cell-based therapeutics, electric field transduction, 3D printing, and prescribed matrices for regenerative medicine. His numerous patents include work in pulse-field delivery, artificial matrices for bone regeneration, electro-spinning methods and materials, mimetic material modification using photoactive lasers, and stem cell procurement and purification.

Apart from his work at VIVEX Biologics, Dr. Ganey is the founder and CTO at SpinPlant GmbH in Leipzig, Germany. He also maintains a faculty appointment at the TRM Facility in Leipzig and is an associate faculty member at Nova Southeastern in Ft. Lauderdale.

Reinaldo Pascual – Co-President and General Counsel

As the founder of Pascual LLC, a specialty corporate law firm, Rey Pascual provides high-level strategic advice and general counsel services to a select group of clients, including VIVEX Biologics.

Before founding Pascual LLC, Mr. Pascual spent 30 years practicing law at several high-level firms in Atlanta and across the US. He most recently served as the managing partner of Paul Hastings LLP, where he chaired the Atlanta corporate group.

Throughout his career, Mr. Pascual has represented numerous clients and has led hundreds of private and public investment and merger and acquisition transactions.

Mr. Pascual holds a Bachelor of Arts degree from Syracuse University and a Juris Doctor degree from Creighton University. He also holds numerous accolades in the Atlanta legal community and has been an early investor to many successful companies.

Mr. Pascual is also the current Vice Chair of the Board of Trustees at Syracuse University and serves on the university’s executive committee.

Jeffery Acuff, VP Sales

Jeffery Acuff has over 25 years of commercial leadership experience in the healthcare industry.
Prior to joining VIVEX Biologics, Mr. Acuff served as Chief Commercial Officer for Predictive Biotech.

He also held leadership positions at GE Healthcare, Bioventus, Varian Medical Systems and Medtronic. Mr. Acuff has an extensive history of sales and management roles within healthcare and has worked in well-established firms and start-up companies alike.

Mr. Acuff holds a Bachelors of Business Administration in Management from The University of Memphis, and Executive Development at Kellogg School of Management, Northwestern University.

Brian Fromhold, Senior Vice President of Finance

Brian Fromhold joined VIVEX in 2017 and is currently the Senior Vice President of Finance. In this role, Mr. Fromhold is responsible for leading corporate and operational finance for the company. Previously, Mr. Fromhold was VIVEX’s Corporate Controller.

Prior to joining VIVEX, Mr. Fromhold worked as Senior Manager of Accounting and Reporting, as well as SEC Reporting Manager for Agilysys. Prior thereto, he held the position of Assurance Manager at PricewaterhouseCoopers.

Mr. Fromhold holds a Bachelor’s degree from Miami University (Ohio) in Accountancy and a Master’s degree in Accountancy from the University of Tennessee.

Tim Maye – Vice President, Operations

Tim Maye joined VIVEX Biologics in 2016 as Vice President of Operations with nearly 25 years of tissue banking experience, including 10 years in various leadership roles in medical device manufacturing.

Prior to joining VIVEX Biologics, Mr. Maye spent close to 20 years with LifeNet, a regenerative medicine company based in Virginia Beach. During his time there, he served in various roles of increasing responsibility throughout the organization, including Vice President of Quality Systems.

In addition to his role at VIVEX Biologics, Mr. Maye serves as the Chairperson of the American Association of Tissue Banks’ Standards Committee, where he leads a collaboration to develop current operating standards for the industry.

Mr. Maye holds a Bachelor of Science degree in Medical Technology from Old Dominion University.

H. Thomas Temple, MD – Chief Medical Officer

Dr. Temple has served as Chief Medical Officer since the inception of VIVEX Biologics. He is a leading orthopedic surgeon who has practiced and published extensively in the field of musculoskeletal oncology.

In addition to managing an active practice, Dr. Temple is a professor of Orthopedics at Nova Southeastern University and Professor Emeritus at the University of Miami. He is an examiner for the American Board of Orthopedic Surgeons and sits on the boards of various medical, collegiate, and local non-profit and for profit entities, including the American Association of Tissue Banks, the Florida Transplantation and Tissue Advisory Board, the Musculoskeletal Tumor Society, Life Alliance, and OsteoLife. Dr. Temple has received numerous professional awards from national and international medical academies and honor societies, as well as military and educational organizations.

Dr. Temple holds a Bachelor’s degree from Harvard University and his Doctor of Medicine Degree from Jefferson Medical College. He then completed his general and orthopedic surgery internships at Walter Reed Army Medical Center and his musculoskeletal oncology fellowship at Harvard University-Massachusetts General Hospital.

Santiago Osorio, CTBS – Vice President of Operations

Santiago Osorio – Vice President, Operations

Santiago Osorio joined VIVEX Biologics in 2015 and is currently the Vice President of Operations. In this role, Mr. Osorio is responsible for planning, coordinating and overseeing the strategic direction of our company operations. Mr. Osorio has also held positions as our Production Manager and Senior Director of Operations.

Prior to joining VIVEX Biologics, Mr. Osorio worked as Recovery Coordinator for the University of Miami, Miller School of Medicine. He holds a Bachelor’s degree from Florida State University and a Master’s in Public Health from the University of Miami.

Michele Pablos, MBA – Vice President of Ortho & Fusion Therapies/Strategic Accounts

Michele Pablos joined VIVEX Biologics in 2015 as Vice President & General Manager of Ortho & Fusion Therapies and Vice President of Strategic Accounts, focused on strengthening VIVEX Biologics’ Ortho & Fusion Therapy platforms while driving growth within key strategic accounts.

Ms. Pablos has more than 20 years of experience in medical sales, marketing, strategic planning, and business development and has been part of more than 15 biologic product launches and line extensions.

Prior to VIVEX Biologics acquiring University of Miami Tissue Bank (UMTB), Ms. Pablos worked as a Director for UMTB, where she played an integral role in developing and launching new domestic and international sales channels as well as establishing a local sales team.

Prior to her time at UMTB, Ms. Pablos held a variety of medical sales roles with Merck Pharmaceuticals, where she spent close to 10 years in progressive roles earning professional sales and management training and winning numerous sales awards. During this time, she sold numerous products and was part of 3 pharmaceutical sales product launches, all billion-dollar plus product lines for Merck.

Ms. Pablos holds a Bachelor of Science degree in Education from Central Michigan University and an MBA in Executive Healthcare Administration from the University of Miami.

Laura Trivette – VP of Health Policy and Reimbursement

Laura Trivette joined VIVEX Biologics in 2019 as the Vice President of Health Policy and Reimbursement. and is responsible for the oversight of market access and reimbursement operations for all product lines. She has more than 25 years of experience in the healthcare industry, 22 years of management training and development experience, and 10 years of call center management experience. She also has extensive experience with new program start-ups, account management, business partnerships, and clinical & health economic outcomes.

Ms. Trivette joined VIVEX Biologics from MiMedx, where she served as the VP for Health Policy and Reimbursement. Prior thereto, she served as the Regional VP for National Accounts at UnitedHealth Group. She also held a number of roles of increasing responsibility at Alere, an Abbott company.

She holds a BBA in Business from LaGrange College, as well as a MEd from Georgia State University.

John A. McCallum – Executive Chairman

John McCallum has served as a Director since the inception of VIVEX Biologics and as the Chairman of the board of directors since 2019. Mr. McCallum also serves as managing partner of JAM Capital Partners, a private investment partnership that makes majority and minority investments in middle market operating companies.

Before forming JAM Capital Partners, Mr. McCallum worked in the Investment Management Division at Goldman Sachs & Co., where he was responsible for developing asset allocation strategies for his clients. Prior to working at Goldman Sachs, Mr. McCallum served as Legislative Aide to the Speaker of the U.S. House of Representatives, the Honorable Newt Gingrich, focusing on budget, banking, and tax issues. Mr. McCallum has also served as Chief Executive Officer of several ventures in both the for-profit and non-profit sectors.

Mr. McCallum currently serves as Director of Rapid Medical, CorMatrix Cardiovascular, Atterx Biotherapeutics, Baler and Compaction Equipment LLC, and Steel Creek Galvanizing. He previously served on the boards of Amendia (acquired by Kohlberg & Co.) and AxoGen (Nasdaq: AXGN), among others.

Mr. McCallum received a Bachelor of Science in Commerce from Washington and Lee University and received his Master’s in Public Administration from the Kennedy School of Government at Harvard University. He also served in the United States Naval Reserve and received an honorable discharge.

Tracy S. Anderson – Founder, Vice Chairman of the Board

Tracy S. Anderson has established an impressive career in the medical market by integrating his expertise as a skilled surgical technician with his corporate experience. A graduate of the University of Georgia, Mr. Anderson began working in the medical industry as a Cardiopulmonary Systems Specialist with Baxter Healthcare. After Baxter, he helped develop two intraocular lens companies, Ioptex, Inc. and Chiron, from the ground up.

In 2002, Mr. Anderson founded Atlanta-based T2MED, Inc., one of the Southeast’s most innovative private companies in the growing spinal device market. In 2008, he merged T2 into Amendia, Inc. as one of its founding partners. With Mr. Anderson as the President of its Sales and Marketing group, Amendia grew to over $85 million in sales before being acquired by private equity for $190 million. In December 2012, Mr. Anderson licensed a unique stem cell lineage from the University of Miami for potential use in general orthopedics. In March of 2013, VIVEX Biologics was spun out from Amendia as a freestanding entity.

In November 2014, Mr. Anderson was instrumental in the acquisition of the University of Miami Tissue Bank, the oldest and one of the most prestigious human tissue facilities in the world. UMTB immediately became VIVEX Biologics, a fully owned subsidiary of VIVEX Biologics, Inc. In July of 2019, Mr. Anderson transitioned from his role as President and CEO to the role of Vice Chairman. He remains a member of the Board of Directors. Through his leadership and innovation, VIVEX Biologics has grown to become a leading tissue and cell therapy company with scientifically based technologies, an unsurpassed patent portfolio, and significant revenue in the spine and orthopedic space.

Throughout his career, Mr. Anderson has partnered with some of the medical industry’s top experts in the areas of general orthopedics, spine surgery, sports medicine, cardiovascular surgery, ophthalmic surgery, and oncology. He is a member of several other professional organizations and advisory boards, including the Advisory Committee for Surgical Technology at Gwinnett Tech in Lawrenceville, Georgia.

Barry Salzman – Co-President and Chief Operating Officer/Vice Chairman

Barry Salzman joined VIVEX Biologics’ Board of Directors in January 2015. Mr. Salzman is currently a Managing Director for Compass Partners LLC, a merchant banking and financial advisory firm that specializes in middle market companies and corporate restructuring. He joined Compass Partners LLC in July 2007, the same time at which he became a Board Member and Principal owner of BP Gamma Medical Supply Company.

Prior to July 2007, Mr. Salzman served as Board Chairman, President, and principal owner of Becker-Parkin Dental Supply Company. After 20 years at Becker-Parkin, Mr. Salzman sold the company to Henry Schein Inc. (NASDAQ: HSIC). From 2008-2012, he served as President of Surgery Works LLC, which was formed by Compass Partners LLC to provide financial management services for ambulatory surgery centers. In 2012 the centers sold a controlling interest to Amsurg (NASDAQ: AMSG). Mr. Salzman has maintained board seats at former Surgery Works, LLC centers and continues to work in a consulting and advisory role to Amsurg.

In 2014, Mr. Salzman founded and became President of Practice Management Works LLC, and in 2016 he accepted a board seat at Checkpoint Therapeutics Inc. (CKPT), an immune-oncology biopharmaceutical company. Mr. Salzman is a 1987 graduate of Brooklyn Law School and is a member in good standing of the New York Bar Association.

Tim Taylor

Tim Taylor has had a dual career in space and medicine for over 40 years. He worked on the Space Shuttle program in Cape Canaveral and continues to serve the Atlas, Delta, and SpaceX programs in launch operations. Mr. Taylor has supported over 40 space shuttle missions and 80 Department of Defense missions as a controller, systems engineer, and field test engineer.

As a principal investigator, Mr. Taylor flew a biomedical experiment on Space Shuttle Columbia in 1991 and, because of the experiment and the resulting recognition, he went on to become the cofounder/Vice President of Engineering at Endius, Inc., a Boston-based surgical device company. Endius (originally known as Aust & Taylor Medical, Inc.) became an early entrant of endoscopic/minimally invasive spine surgery and has become known as the pioneering company in endoscopic spine surgery. In March 2007, the world’s largest orthopedic company, Zimmer, acquired Endius in a private transaction. Before being acquired, Endius was one of the fastest- growing spinal device and implant companies in the US. After hiring a seasoned CEO, Tim resigned from Endius in 2000 and joined Amendia/Spinal Elements as Chairman of the Board. He then became Chairman of the Board of VIVEX Biologics.

Mr. Taylor continues to support Department of Defense launches from Cape Canaveral as well as advanced biomedical ventures, bridging the gap of aerospace and biomedical technologies. He holds over 40 patents, serves on medical and nonprofit boards, and published the book Launch Fever.

Richard Perlman, MBA

Richard Perlman is a member of the Board of Directors of VIVEX Biologics. He is also a co-founder and Executive Chairman of ExamWorks Group, Inc., the global leader in the independent medical exam industry. Since its founding in 2008, ExamWorks has grown revenues to $1.5 billion and is the market leader in the US, the UK, Australia, and Canada.

Prior to ExamWorks, Mr. Perlman was Executive Chairman of TurboChef Technologies, Inc. (NASDAQ:OVEN), the world leader in speed cook technology (of which he acquired control in 2003 and sold to Middleby Corporation (NASDAQ:MIDD) in 2008), PracticeWorks, Inc. (NASDAQ:PRWK), the world leader of dental practice management software and digital radiography (which he sold to Eastman Kodak (NYSE:EK) in 2003), and AMICAS (NASDAQ:AMCS), a leading medical practice management software company (which was sold in two transactions to Cerner Corporation (NASDAQ:CERN) and Merge Technologies, Inc. (NASDAQ:MRGS).

Mr. Perlman is also the Chairman of Compass Partners, LLC, a merchant banking firm specializing in middle market companies, which he founded in 1995. He sits on the boards of various private companies in which Compass has invested.

Mr. Perlman is the donor of the Perlman Grand Prize for the Wharton Business Plan Competition and serves on the Executive Advisory Board of the Wharton Undergraduate School and the Wharton Entrepreneurial Advisory Board. He is a Trustee of the James Beard Foundation and a board member of the Sun Valley Center for the Arts and the Boys and Girls Club of Sarasota.

Mr. Perlman is a graduate of the Wharton School of the University of Pennsylvania and received his Master of Business Administration from the Columbia University Graduate School of Business.

James K. Price

James K. Price is a member of the Board of Directors of VIVEX Biologics. He is the co-founder and Chief Executive Officer of ExamWorks. Previously, Mr. Price served as Co-Chairman of the Board and Co-Chief Executive Officer of ExamWorks from July 2008.

From October 2003 to January 2009, Mr. Price served as President, Chief Executive Officer, and Director of TurboChef Technologies, Inc. He served as President, Chief Executive Officer, and Director of PracticeWorks, Inc. from March 2001 until its acquisition by the Eastman Kodak Company in October 2003. Mr. Price was a co-founder of AMICAS, Inc. (formerly VitalWorks Inc.) and served as its Executive Vice President and Secretary from July 1997 until the completion of the spin-off of PracticeWorks, Inc. in March 2001.

Mr. Price also served as an executive officer of American Medcare. He also co-founded and was an executive officer of International Computer Solutions, both of which provided healthcare software systems and information services and were acquired by VitalWorks Inc.

Mr. Price sits on the Board of Directors of several privately held companies and non-profit organizations. He holds a Bachelor of Business Administration in Marketing from the University of Georgia.

J. Miguel Fernandez de Castro, MAcc

J. Miguel Fernandez de Castro has been a member of Board of Directors of VIVEX Biologics since 2014. Currently, he also serves as Chief Financial Officer and Senior Executive Vice President for Examworks, a leading provider of independent medical examinations, peer reviews, and bill reviews, among other services.

Previously, Mr. Fernandez de Castro was Senior Vice President and Chief Financial Officer of TurboChef Technologies, Inc., from October 2007 to February 2009, and Vice President of Finance and Controller from April 2004 to February 2009. From October 2003 to February 2004, Mr. Fernandez de Castro served as the Controller of PracticeWorks, Inc., and served as Director of Financial Reporting from August 2000 until its acquisition by the Eastman Kodak Company in October 2003, during which time PracticeWorks was a publicly traded company. Mr. Fernandez de Castro served as Manager of Financial Reporting of AMICAS, Inc. (formerly VitalWorks Inc.) from August 2000 until the completion of the spin-off of PracticeWorks, Inc. in March 2001. He began his career in the audit services group of BDO Seidman, LLP, which provides assurance, tax, financial advisory and consulting services.

Mr. Fernandez de Castro is a Certified Public Accountant and a member of the Georgia Society of CPAs. He received a Bachelor of Arts in Economics and Spanish and a Master of Accountancy from the University of North Carolina at Chapel Hill.

U. Bertram Ellis, Jr., MBA

U. Bertram Ellis, Jr. is a member of the Board of Directors of VIVEX Biologics and a serial entrepreneur and investor, having founded and operated numerous companies, both private and public.

Mr. Ellis serves as the Chief Executive Officer and Chairman of Ellis Capital, a consulting and investment firm primarily focused on the media, technology, healthcare, and fintech industries. He primarily manages acquisitions, strategic relationships, and fundraising for his companies, but has also been integrally involved in sales, operations, and strategic planning. He has managed multiple high growth companies and achieved significant returns for his investors.

Mr. Ellis previously founded and served as Chief Executive Officer of Act III Broadcasting, and Ellis Communications. He was a founding investor and board member of WebMD, and Amendia.

Mr. Ellis holds a Bachelor of Arts in Economics and a Master of Business Administration from the Darden Graduate School of Business Administration at the University of Virginia.

Corporate Offices

MIAMI
2430 NW 116th Street
Miami, FL 33167

ATLANTA
3200 Windy Hill Road,
Suite 1650W
Atlanta, GA 30339